Our findings implicate advanced disease stage, greater tumor depth (Breslow thickness), regional lymph node involvement, and acral melanoma subtype as variables associated with a higher likelihood of recurrence during anti-PD-1 treatment. This evidence concerns the gene PDCD1 and neoplasm.